Chinese Pharmaceutical Market Study by Visiongain

10 Feb 2012 • by Natalie Aster

The government's Healthy China 2020 plan will mean up to $1.4 trillion invested, according to the report “Chinese Pharmaceutical Market 2012-2022” by Visiongain. Medical R&D in China is gaining prominence. Assess the trends behind its emergence as a biopharmaceutical hub, reviewing progress in outsourced research and manufacturing.

Discover sales predictions at overall market and submarket levels. The study gives business research, analysis and opinion for drug sales in China. Data and trends are thoroughly analysed in the study. The report also shows market potential revenues to 2022, discussing opportunities and developments.

See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs.

See the effects of rising purchase power and widening medical coverage, discovering prospects from 2012. Find information, calculations and views in this report.

Report Details:

Chinese Pharmaceutical Market 2012-2022
Published: December, 2011
Pages: 158
Price: US$ 2.642,00

Visiongain's study provides data, analysis and opinion aiming to benefit any market research, calculations, meetings and presentations.

More information can be found in the report “Chinese Pharmaceutical Market 2012-2022” by Visiongain.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970